CoChat

Effect of Bromocriptine‐QR (a Quick‐Release Formulation of Bromocriptine Mesylate) on Major Adverse Cardiovascular Events in Type 2 Diabetes Subjects

Open access
Gaziano, J. Michael, Cincotta, Anthony H., Vinik, Aaron, Blonde, Lawrence, Bohannon, Nancy, Scranton, Richard · 2012 · Journal of the American Heart Association
Cited by 93

The DOI matches its Crossref record; 4 of the 4 references it cites were found in a registry or an index.

Abstract

Background: Bromocriptine‐ QR (a quick‐release formulation of bromocriptine mesylate), a dopamine D2 receptor agonist, is a US F ood and D rug A dministrration–approved treatment for type 2 diabetes mellitus ( T2DM ). A 3070‐subject randomized trial demonstrated a significant, 40% reduction in relative risk among bromocriptine‐ QR ‐treated subjects in a prespecified composite cardiovascular ( CV ) end point that included ischemic‐related (myocardial infarction and stroke) and nonischemic‐related (hospitalization for unstable angina, congestive heart failure [ CHF ], or revascularization surgery) end points, but did not include cardiovascular death as a component of this composite. The present investigation was undertaken to more critically evaluate the impact of bromocriptine‐ QR on cardiovascular outcomes in this study subject population by (1) including CV death in the above‐described original composite analysis and then stratifying this new analysis on the basis of multiple demographic subgroups and (2) analyzing the influence of this intervention on only the “hard” CV end points of myocardial infarction, stroke, and CV death (major adverse cardiovascular events [ MACE s]). Methods and Results: Three thousand seventy T2DM subjects on stable doses of ≤2 antidiabetes medications (including insulin) with HbA1c ≤10.0 (average baseline HbA1c =7.0) were randomized 2:1 to bromocriptine‐ QR (1.6 to 4.8 mg/day) or placebo for a 52‐week treatment period. Subjects with heart failure ( N ew Y ork H eart C lasses I and II) and precedent myocardial infarction or revascularization surgery were allowed to participate in the trial. Study outcomes included time to first event for each of the 2 CV composite end points described above. The relative risk comparing bromocriptine‐ QR with the control for the cardiovascular outcomes was estimated as a hazard ratio with 95% confidence interval on the basis of C ox proportional hazards regression. The statistical significance of any between‐group difference in the cumulative percentage of CV events over time (derived from a K aplan– M eier curve) was determined by a log‐rank test on the intention‐to‐treat population. Study subjects were in reasonable metabolic control, with an average baseline HbA1c of 7.0±1.1, blood pressure of 128/76±14/9, and total and LDL cholesterol of 179±42 and 98±32, respectively, with 88%, 77%, and 69% of subjects being treated with antidiabetic, antihypertensive, and antihyperlipidemic agents, respectively. Ninety‐one percent of the expected person‐year outcome ascertainment was obtained in this study. Respecting the CV ‐inclusive composite cardiovascular end point, there were 39 events (1.9%) among 2054 bromocriptine‐ QR ‐treated subjects versus 33 events (3.2%) among 1016 placebo subjects, yielding a significant, 39% reduction in relative risk in this end point with bromocriptine‐ QR exposure ( P =0.0346; log‐rank test) that was not influenced by age, sex, race, body mass index, duration of diabetes, or preexisting cardiovascular disease. In addition, regarding the MACE end point, there were 14 events (0.7%) among 2054 bromocriptine‐ QR ‐treated subjects and 15 events (1.5%) among 1016 placebo‐treated subjects, yielding a significant, 52% reduction in relative risk in this end point with bromocriptine‐ QR exposure ( P <0.05; log‐rank test). Conclusions: These findings reaffirm and extend the original observation of relative risk reduction in cardiovascular adverse events among type 2 diabetes subjects treated with bromocriptine‐ QR and suggest that further investigation into this impact of bromocriptine‐ QR is warranted. Clinical Trial Registration: URL: http://clinicaltrials.gov . Unique Identifier: NCT00377676

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1161/jaha.112.002279

Cites

4 of 4 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 4 references

Cited by

See all 93

Metadata

Authors
Gaziano, J. M., Cincotta, A. H., Vinik, A., Blonde, L., Bohannon, N., & Scranton, R.
Venue
Journal of the American Heart Association
Published
2012-09-26
Volume
1
Issue
5
Pages
e002279-e002279
ISSN
2047-9980 (ISSN-L)
OpenAlex
W2118123147
Cited by
93
References
4
FWCI
5.29
Type
journal article
Language
en
Open access
gold

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Effect of Bromocriptine‐QR (a Quick‐Release Formulation of Bromocriptine Mesylate) on Major Adverse Cardiovascular Events in Type 2 Diabetes Subjects. https://app.cochat.ai/papers/10.1161/jaha.112.002279
The paper
Gaziano, J. M., Cincotta, A. H., Vinik, A., Blonde, L., Bohannon, N., & Scranton, R. (2012). Effect of Bromocriptine‐QR (a Quick‐Release Formulation of Bromocriptine Mesylate) on Major Adverse Cardiovascular Events in Type 2 Diabetes Subjects. Journal of the American Heart Association. https://doi.org/10.1161/jaha.112.002279

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.